Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Financial Disclosure
The University of Texas System provided all data on outside professional activity of faculty and staff from all campuses from 2016 to 2019. All university employees are required to disclose outside work or activities, which are reviewed for potential conflicts of interest and conflicts of commitment.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stanley Watowich
University of Texas Med Br Galveston, Department: Biochemistry & Molecular Bio
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ridgeline Therapeutics, LLC
Company was established in January 2013. It has been mostly inactive since that time. However, beginning in Summer 2018 it has begun to apply for non-dilutive funding. none Founder and sole owner of Ridgeline Therapeutics LLC, a startup company (established in 2013). In September 2018, the company distributed profits of $ that were the result of a recently awarded NIH STTR grant. We created Ridgeline Therapeutics to commercialize discoveries made in our laboratory at UTMB. These discoveries have been patented by UTMB. Ridgeline is in the process of negotiating a License for IP that was filed with US Patent Office (and PCT) on Mar 30, 2018. In addition, the company has submitted two NIH STTR Phase 1 grants; these have been recently funded. UTMB is listed as the non-profit Sub-Awardee on both STTR proposals. Dr. Jonathan Hommel and Dr. Christopher Fry each serve as PI for one for the STTR grant Sub-Awards. Drs. Hommel and Fry have no ownership or role e.g., they are not consultants/employees/etc) in the company and receive no compensation from Ridgeline. This arrangement has been made with the support, close collaboration, and cooperation of the UTMB Office of Technology Transfer. The company's recent efforts to commercialize our laboratory's discoveries has not affected fully performing my institutional responsibilities.
Filed on November 12, 2018.
Tell us what you know about Stanley Watowich's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Stanley Watowich”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stanley Watowich | University of Texas Med Br Galveston | Financial Disclosure | Oak Ridge Associated Universities | |
| Stanley Watowich | University of Texas Med Br Galveston | Financial Disclosure | Southwest Electronic Energy Medical Research Institute | |
| Stanley Watowich | University of Texas Med Br Galveston | Financial Disclosure | Ridgeline Therapeutics, LLC | |
| Stanley Watowich | University of Texas Med Br Galveston | Financial Disclosure | Southwest Electronic Energy Medical Research Institute | |
| Stanley Watowich | University of Texas Med Br Galveston | Financial Disclosure | Ridgeline Therapeutics, LLC |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.